Evidence map›Paper›PMID 32269520›Full record

ArticleFrontiers in synaptic neuroscience2020

Stereotactically Injected Kv1.2 and CASPR2 Antisera Cause Differential Effects on CA1 Synaptic and Cellular Excitability, but Both Enhance the Vulnerability to Pro-epileptic Conditions.

Timo Kirschstein, Erika Sadkiewicz, Gerda Hund-Göschel, Juliane Becker, Xiati Guli, Steffen Müller, Marco Rohde, Dora-Charlotte Hübner, Hannes Brehme, Stephan Kolbaske and 7 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in synaptic neuroscience, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Refining Genotypes and Phenotypes inInternational journal of molecular sciences · 2021
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 2 institutions in 1 country.

Timo KirschsteinOscar Langendorff Institute of Physiology, University of Rostock, Rostock, Germany.
Erika SadkiewiczOscar Langendorff Institute of Physiology, University of Rostock, Rostock, Germany.
Gerda Hund-GöschelOscar Langendorff Institute of Physiology, University of Rostock, Rostock, Germany.
Juliane BeckerOscar Langendorff Institute of Physiology, University of Rostock, Rostock, Germany.
Xiati GuliOscar Langendorff Institute of Physiology, University of Rostock, Rostock, Germany.
Steffen MüllerOscar Langendorff Institute of Physiology, University of Rostock, Rostock, Germany.
Marco RohdeOscar Langendorff Institute of Physiology, University of Rostock, Rostock, Germany.
Dora-Charlotte HübnerOscar Langendorff Institute of Physiology, University of Rostock, Rostock, Germany.
Hannes BrehmeDepartment of Neurology, University of Rostock, Rostock, Germany.
Stephan KolbaskeDepartment of Neurology, University of Rostock, Rostock, Germany.
Katrin PorathOscar Langendorff Institute of Physiology, University of Rostock, Rostock, Germany.
Tina SellmannOscar Langendorff Institute of Physiology, University of Rostock, Rostock, Germany.
Annette GroßmannInstitute of Diagnostic and Intervention Radiology, University of Rostock, Rostock, Germany.
Matthias WittstockDepartment of Neurology, University of Rostock, Rostock, Germany.
Steffen SyrbeClinik for Pediatric and Adolescent Medicine, University of Heidelberg, Heidelberg, Germany.
Alexander StorchDepartment of Neurology, University of Rostock, Rostock, Germany.
Rüdiger KöhlingOscar Langendorff Institute of Physiology, University of Rostock, Rostock, Germany.
University of Rostock · DEHeidelberg University · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeWe present a case of voltage-gated potassium channel (VGKC) complex antibody-positive limbic encephalitis (LE) harboring autoantibodies against Kv1.2. Since the patient responded well to immunotherapy, the autoantibodies were regarded as pathogenic. We aimed to characterize the pathophysiological role of this antibody in comparison to an antibody against the VGKC-associated protein contactin-associated protein-2 (CASPR2).

methodsStereotactic injection of patient sera (anti-Kv1.2-associated LE or anti-CASPR2 encephalopathy) and a control subject was performed into the hippocampus of the anesthetized rat

resultsWe observed that the slope of the field excitatory postsynaptic potential (fEPSP) was significantly increased at Schaffer collateral-CA1 synapses in anti-Kv1.2-treated and anti-CASPR2-treated rats, but not at medial perforant path-dentate gyrus synapses. The increase of the fEPSP slope in CA1 was accompanied by a decrease of the paired-pulse ratio in anti-Kv1.2, but not in anti-CASPR2 tissue, indicating presynaptic site of anti-Kv1.2. In addition, anti-Kv1.2 tissue showed enhanced LTP in CA1, but dentate gyrus LTP remained unaltered. Importantly, LTP in slices from anti-CASPR2-treated animals did not differ from control values. Intracellular recordings from CA1 neurons revealed that the resting membrane potential and a single action potential were not different between anti-Kv1.2 and control tissue. However, when the depolarization was prolonged, the number of action potentials elicited was reduced in anti-Kv1.2-treated tissue compared to both control and anti-CASPR2 tissue. In contrast, polyspike discharges induced by removal of Mg

conclusionPatient serum containing anti-Kv1.2 facilitates presynaptic transmitter release as well as postsynaptic depolarization at the Schaffer-collateral-CA1 synapse, but not in the dentate gyrus. As a consequence, both synaptic transmission and LTP in CA1 are facilitated and action potential firing is altered. In contrast, anti-CASPR2 leads to increased postsynaptic potentials, but without changing LTP or firing properties suggesting that anti-Kv1.2 and anti-CASPR2 differ in their cellular effects. Both patient sera alter susceptibility to epileptic conditions, but presumably by different mechanisms.

Indexed as

limbic encephalitislong-term potentiationspike frequency adaptationsynaptic transmissionvoltage-gated potassium channel

Identifiers

PMID32269520
PMCPMC7110982
OpenAlexW3013112092

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.